Skip to main content
Xin Wang, MD, Radiation Oncology, Minneapolis, MN

XinWangMD

Radiation Oncology Minneapolis, MN

Associate Professor, Therapeutic Radiology, University of Minnesota Medical School

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

  • Office

    The Center For Prostate Cancer
    420 Delaware Street Se, Mayo Building, Fourth Floor
    Minneapolis, MN 55455
    Phone+1 612-625-6401
  • Is this information wrong?

Education & Training

  • National Capital Consortium
    National Capital ConsortiumResidency, Radiation Oncology, 1992 - 1995
  • One Brooklyn Health System
    One Brooklyn Health SystemInternship, Transitional Year, 1991 - 1992
  • Capital University of Medical Sciences
    Capital University of Medical SciencesClass of 1982

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 1993 - 2026
  • MN State Medical License
    MN State Medical License 1997 - 2025
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Author Correction: Necroptosis Microenvironment Directs Lineage Commitment in Liver Cancer  
    Xin Wang, MD, Nature
  • Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances  
    Mario Strazzabosco, Florin M Selaru, Gregory J Gores, Xin Wei Wang, Hepatology

Press Mentions

  • Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of Venetoclax
    Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of VenetoclaxDecember 20th, 2023
  • Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)
    Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)May 29th, 2024